In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Abstract Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6 (NCT03173092) enrolled transplant-ineligible pati...
Main Authors: | Robert M. Rifkin, Saulius K. Girnius, Stephen J. Noga, Ruemu E. Birhiray, Suman Kambhampati, Sudhir Manda, Roger M. Lyons, Habte A. Yimer, Dasha Cherepanov, Eric Lloyd, Presley Whidden, Joshua Richter |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-09-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-023-00912-9 |
Similar Items
-
PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
by: Saulius K. Girnius, et al.
Published: (2023-08-01) -
P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
by: R. M. Rifkin, et al.
Published: (2022-06-01) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01) -
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01)